San Diego, CA, August 29, 2024 – Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory (I&I) diseases will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference held at the New York Marriott Marquis, New York, NY. Jonathan Wang, Chairman and Chief Executive Officer will represent Inmagene in a session scheduled on Friday, September 6, 2024, 1:05 PM – 1:40 PM Eastern Time.
About Inmagene
Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor with an extended half-life and pharmacodynamic effect, enabling its potential for once-daily dosing, recently completed the Phase 1 multiple ascending dose (MAD) study and is ready for Phase 2 development.
For more information, please visit www.inmagenebio.com.
Forward-Looking Statements
This press release contains forward-looking statements. While Inmagene believes the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.
For further information, please contact:
Inmagene:
Anna Vardanyan, MD, PhD
SVP of Corporate and Business Development
vardanyana@inmagenebio.com
Investor Relations:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com